Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study.

ZOGHİ, MEHDİ; Kaya, Hakki; ÇAVUŞOĞLU, YÜKSEL; Aksakal, Enbiya; Demir, Serafettin; Yucel, Ceyhun; Mutlu, Hasim; Ergene, ASIM; YILMAZ, MEHMET

doi:10.5543/tkda.2016.10733

Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study.

Atıf İçin Kopyala

ZOGHİ M., Kaya H., ÇAVUŞOĞLU Y., Aksakal E., Demir S., Yucel C., ...Daha Fazla

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, cilt.44, sa.6, ss.457-65, 2016 (Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 44 Sayı: 6
Basım Tarihi: 2016
Doi Numarası: 10.5543/tkda.2016.10733
Dergi Adı: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.457-65
Anahtar Kelimeler: Functional capacity, heart failure, medical adherence, socioeconomic status, IDIOPATHIC DILATED CARDIOMYOPATHY, BETA(1)-ADRENERGIC RECEPTOR, ELDERLY-PATIENTS, ASSOCIATION, METOPROLOL, IMPACT, CARVEDILOL, ALPHA(2C)DEL322-325, PHARMACOKINETICS, RECOMMENDATIONS
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objective: The present objective was to determine frequency of Arginine389Glycine (Arg389Gly) and Cytochrome p450 2D6*10 (Cyp2D6*10) polymorphism in cases of heart failure-reduced ejection fraction (HFREF), and to evaluate the influence of the polymorphisms in response to beta-blocker (BB) therapy.